Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
Company to host conference call on Wednesday, March 17 at 8:30 am EST
- First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
- Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
- Treatment-emergent adverse events were transient and manageable